المؤلفون: Levunlieva,Elisaveta, Kaneva,Anna, Lekova,Reneta, Nenova - Karakasheva,Kiparisiya, Dimitrov,Lyubomir

المصدر: Bulgarian Cardiology 28(1): 120-134

مصطلحات موضوعية: вродена сърдечна малформация, обща камера, Fontan-циркулация, силденафил, хемодинамика congenital heart defect, single ventricle, Fontan circulation, sildenafil, hemodynamics

وصف الملف: text/html

Relation: info:eu-repo/semantics/altIdentifier/eissn/2683-1015; info:eu-repo/semantics/altIdentifier/pissn/1310-7488

الاتاحة: https://doi.org/10.3897/bgcardio.28.e82260
https://journal.bgcardio.org/article/82260/

المؤلفون: MARTINIUC, Constantin, PISARENCO, Serghei, SIMIONICA, Iurie

المصدر: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 71 No. 3 (2021): Medical Sciences; 254-257 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 71 Nr. 3 (2021): Ştiinţe medicale; 254-257 ; Вестник Академии Наук Молдовы. Медицина; Том 71 № 3 (2021): Медицина; 254-257 ; 1857-0011 ; 10.52692/1857-0011.2021.3-71

مصطلحات موضوعية: идиопатическая легочная гипертензия, силденафил, легочная гемодинамика, hipertensiune pulmonară idiopatică, sildenafil, hemodinamică pulmonară, idiopathic pulmonary hypertension, pulmonary haemodynamics

وصف الملف: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3391/3395; https://bulmed.md/bulmed/article/view/3391

الاتاحة: https://bulmed.md/bulmed/article/view/3391
https://doi.org/10.52692/1857-0011.2021.3-71.49

المصدر: Медицинский совет, Vol 0, Iss 5-6, Pp 78-82 (2019)

مصطلحات موضوعية: легочная гипертензия, сердечная недостаточность, силденафил, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/3603; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/24d88f285d854219a42c27ff62c9f890

المؤلفون: Trishch, Volodymyr, Mysak, Andrii

المصدر: Health of Man; No. 2 (2021); 71-78 ; Здоровье мужчины; № 2 (2021); 71-78 ; Здоров'я чоловіка; № 2 (2021); 71-78 ; 2412-5547 ; 2307-5090

مصطلحات موضوعية: еректильна дисфункція, силденафіл, L-аргінін, Строндекс, Бодрекс, 616-08 616.69, эректильная дисфункция, силденафил, L-аргинин, erectile dysfunction, sildenafil, L-arginine, Strondex, Bodrex

وصف الملف: application/pdf

Relation: http://health-man.com.ua/article/view/237551/237042; http://health-man.com.ua/article/view/237551

الاتاحة: http://health-man.com.ua/article/view/237551
https://doi.org/10.30841/2307-5090.2.2021.237551

المؤلفون: G. G. Rodionov, I. I. Shantyr, I. E. Ushal, E. V. Svetkina, E. A. Kolobova, K. A. Zakharov, Г. Г. Родионов, И. И. Шантырь, И. Э. Ушал, Е. В. Светкина, Е. А. Колобова, К. А. Захаров

المساهمون: The bioequivalence study of sildenafil dosage forms was performed according to Protocol No. PT-KI-005-001-01 Version 1.0 of January 27, 2017. “An open-label, randomised, balanced, cross-over, single-dose, two-period, two-sequence bioequivalence study of 50 mg of Gent, metered-dose oral spray, 12.5 mg/dose, produced by OOO NPO FarmVILAR, Russia, and 50 mg of Viagra® , film-coated tablets, 50 mg, produced by Fareva Amboise, France (marketing authorisation holder—Pfizer Inc., USA) in adult healthy volunteers under fasting”. The study was sponsored by Farmamed LLC, Russia., Исследование биоэквивалентности лекарственных форм силденафила проведено по Протоколу № ПТ-КИ-005-001-01 Версия 1.0 от 27.01.2017 г. «Открытое рандомизированное сбалансированное перекрестное исследование биоэквивалентности в двух периодах, двух последовательностях с однократным приемом внутрь 50 мг лекарственного препарата Джент, спрей для приема внутрь дозированный, 12,5 мг/доза, ООО НПО «ФармВИЛАР», Россия, и 50 мг лекарственного препарата Виагра® , таблетки, покрытые пленочной оболочкой, 50 мг, Фарева Амбуаз, Франция (держатель РУ — Пфайзер Инк, США) у взрослых здоровых добровольцев натощак». Спонсор исследования ООО «Фармамед», Россия.

المصدر: Regulatory Research and Medicine Evaluation; Том 10, № 3 (2020); 192-200 ; Регуляторные исследования и экспертиза лекарственных средств; Том 10, № 3 (2020); 192-200 ; 2619-1172 ; 1991-2919

مصطلحات موضوعية: ВЭЖХ-МС/МС, sildenafil, N-desmethyl sildenafil, bioequivalence, HPLC-MS/MS, силденафил, N-десметилсилденафил, биоэквивалентность

وصف الملف: application/pdf

Relation: https://www.vedomostincesmp.ru/jour/article/view/305/407; Ахвледиани НД, Матюхов ИП. Современное место силденафила в лечении эректильной дисфункции. Урология. 2018;(2):142–6. https://doi.org/10.18565/urology.2018.2.142-146; Кузнецов ИЭ, Науменко ЕА, Резниченко НК, Костюк АЮ, Савяк РП, Олейников ДС. Разработка и валидация методики количественного определения силденафила и N-десметилсилденафила с помощью ВЭЖХ-МС/МС в плазме крови человека. ScienceRise: Pharmaceutical Science. 2017;1(5):22–32. https://doi.org/10.15587/2519-4852.2017.92823; Tripathi AS, Sheikh I, Dewani AP, Shelke PG, Bakal RL, Chandewar AV, et al. Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies. Saudi Pharm J. 2013;21(3):317–21. https://doi.org/10.1016/j.jsps.2012.09.003; Reddy BPK, Reddy YR. Validation and stability indicating RP-HPLC method for the determination of sildenafil citrate in pharmaceutical formulations and human plasma. J Chem. 2008;5(S2):1117–22. https://doi.org/10.1155/2008/682924; Al-Ghazawi M, Tutunji M, AbuRuza S. Simultaneous determination of sildenafil and N-desmethyl sildenafil in human plasma by high-performance liquid chromatography method using electrochemical detection with application to a pharmacokinetic study. J Pharm Biomed Anal. 2007;43(2):613–8. https://doi.org/10.1016/j. jpba.2006.07.028; Haque A, Kumar N. Pharmacokinetics studies of sildenafil and its metabolite piperazine N-desmethyl sildenafil by using LC-MS/MS in human plasma. Int J Drug Dev Res. 2014;6(2):130–5.; Samah SA, Bendas ER, Abdel-Fattah AA, Hegazy MA. Reversed phase high performance liquid chromatographic method for determination of sildenafil in human plasma and its application to a bioequivalence study. Bioeq Bioav Int J. 2017;1(3):1–7. https://doi.org/10.23880/BEBA-16000113; Ярошенко ДВ, Григорьев АВ, Сидорова АА, Карцова ЛА. Хроматографическое определение силденафила в плазме крови с использованием спектрофотометрического и масс-спектрометрического детектирования. Журнал аналитической химии. 2013;68(9):886–94. https://doi.org/10.1134/S1061934813090128; Simiele M, Pensi D, Pasero D, Ivaldi F, Rinaldi M, Di Perri G, et al. Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1001:35–40. https://doi.org/10.1016/j.jchromb.2015.07.023; El-Bagary R, Azzazy HME, ElKady EF, Farouk F. Simultaneous determination of sildenafil citrate and some nitric oxide releasing drugs in human plasma using UPLC MS/MS. Clin Biochem. 2014;47(7–8):654–6. https://doi.org/10.1016/j.clinbiochem.2014.03.009; https://www.vedomostincesmp.ru/jour/article/view/305

الاتاحة: https://www.vedomostincesmp.ru/jour/article/view/305
https://doi.org/10.30895/1991-2919-2020-10-3-192-200

المؤلفون: I. Tyuzikov A., A. Smirnov V., L. Smirnova V., I. Lesnikova V., И. Тюзиков А., А. Смирнов В., Л. Смирнова В., И. Лесникова В.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2018); 192-202 ; Медицинский Совет; № 21 (2018); 192-202 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-21

مصطلحات موضوعية: sildenafil, cardiomyopathy, diabetic polyneuropathy, chronic kidney disease (CKD), pregnancy pathology, female sexual dysfunctions (FSD), male infertility, cancer, силденафил, кардиомиопатия, диабетическая полинейропатия, хроническая болезнь почек (ХБП), патология беременности, женские сексуальные дисфункции (ЖСД), мужское бесплодие, рак

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2837/2781; Hatzimouratidis K., Giuliano F., Moncada I., Muneer A., Salonia A., Verze P., et al. Management of Male Sexual Dysfunction. EAU Guideline, 2017.; Gravas S., Cornu J.N., Drake M.J., Gacci M., Gratzke C., Herrmann T.R.W., et al. Management of Non-neurogenic Male LUTS. EAU Guideline, 2017.; Derry F., Hultling C., Seftel A.D., Sipski M.L. Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urol. 2002; 60(2 Suppl 2): 49–57.; Vrentzos G.E., Paraskevas K.I., Mikhailidis D.P. Erectile dysfunction: a marker of early coronary heart disease. Hellenic J Cardiol. 2007; 48(4): 1851–191.; Guay A.T. ED2: erectile dysfunction – endothelial dysfunction. Endocrinol Metab Clin North Am. 2007; 36(2): 453–463. DOI:10.1016/j.ecl.2007.03.007.; Ito M., Nishikawa M., Fujioka M., Miyahara M., Isaka N., Shiku H., et al. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal. 1996; 8: 575–581. DOI:10.1016/S0898-6568(96)00112-X.; Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999; 83: 3C–12C.; Loughney K., Hill T.R., Florio V.A., Uher L., Rosman G.J., Wolda S.L., et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3’,5’-cyclic nucleotide phosphodiesterase. Gene. 1998; 216:139–147.; Das A., Xi L., Kukreja R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem. 2008; 283: 29572–29585. DOI:10.1074/jbc.M801547200. Epub 2008 Aug 21.; Senzaki H., Smith C.J., Juang G.J., Isoda T., Mayer S.P., Ohler A., et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates betaadrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001; 15: 1718–1726. DOI:10.1096/fj.00-0538com.; Nagendran J., Archer S.L., Soliman D., Gurtu V., Moudgil R., Haromy A., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007; 116: 238–248. DOI:10.1161/CIRCULATIONAHA.106.655266.; Pokreisz P., Vandenwijngaert S., Bito V., Van den Bergh A., Lenaerts I., Busch C., et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119:408–416. DOI:10.1161/CIRCULATIONAHA.108.822072. Epub 2009 Jan 12.; Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11:214–222. DOI:10.1038/nm1175.; Vandeput F., Krall J., Ockaili R., Salloum F.N., Florio V., Corbin J.D., et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009; 330: 884–891. DOI:10.1124/jpet.109.154468.; Lukowski R., Krieg T., Rybalkin S.D., Beavo J., Hofmann F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. Trends Pharmacol Sci. 2014; 35: 404–413. DOI:10.1016/j.tips.2014.05.003. Epub 2014 Jun 16.; Lukowski R., Rybalkin S.D., Loga F., Leiss V., Beavo J.A., Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA. 2010; 107: 5646–5651. DOI:10.1073/pnas.1001360107. Epub 2010 Mar 8.; Ockaili R., Salloum F., Hawkins J., Kukreja R.C. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 2002; 283: H1263–H1269.DOI:10.1152/ajpheart.00324.2002.; Salloum F.N., Takenoshita Y., Ockaili R.A., Daoud V.P., Chou E., Yoshida K., Kukreja RC. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol. 2007; 42: 453–458. DOI:10.1016/j.yjmcc.2006.10.015.; Bremer Y.A., Salloum F., Ockaili R., Chou E., Moskowitz W.B., Kukreja R.C. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res. 2005; 57: 22–27. DOI:10.1186/s13054-014-0641-7.; Wang X., Fisher P.W., Xi L., Kukreja R.C. Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafilinduced late cardioprotection. J Mol Cell Cardiol. 2008; 44: 105–113. DOI:10.1016/j.yjmcc.2007.10.006.; Salloum F.N., Abbate A., Das A., Houser J.E., Mudrick C.A., Qureshi I.Z., et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008; 294: H1398– H1406. DOI:10.1152/ajpheart.91438.2007.; Salloum F.N., Das A., Thomas C.S., Yin C., Kukreja R.C. Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. J Mol Cell Cardiol. 2007; 43: 545–551. DOI:10.1016/j.yjmcc.2007.08.014.; Chau V.Q., Salloum F.N., Hoke N.N., Abbate A., Kukreja R.C. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011; 300: H2272–H2279. DOI:10.1152/ajpheart.00654.2010. Epub 2011 Mar 11.; Noma K., Oyama N., Liao J.K. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006; 290:C661–C668. DOI:10.1152/ajpcell.00459.2005.; Zusman R.M. Cardiovascular data on sildenafil citrate. Am J Cardiol. 1999; 5(83): 1-2.; Guazzi M., Tumminello G., Di Marco F., Guazzi M.D. Influences of Sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther. 2004; 76: 371–378. DOI:10.1016/j.clpt.2004.06.003.; Lewis G.D., Lachmann J., Camuso J., Lepore J.J., Shin J., Martinovic M.E., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007; 115: 59–66. DOI:10.1161/CIRCULATIONAHA.106.626226.; Muller-Ehmsen J., Whittaker P., Kloner R.A., Dow J.S., Sakoda T., Long T.I., et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol. 2002; 34:107–116. DOI:10.1006/jmcc.2001.1491.; Pagani F.D., Der Simonian H., Zawadzka A., Wetzel K., Edge A.S., Jacoby D.B., et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol. 2003; 41:879–888.; Hoke N.N., Salloum F.N., Kass D.A., Das A., Kukreja R.C. Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells. 2012; 30: 326–335. DOI:10.1002/stem.789.; Kukreja R.C. Sildenafil and cardioprotection. Curr Pharm Des. 2013;19(39):6842–6847.; Handa P., Tateya S., Rizzo N.O., Cheng A.M., Morgan-Stevenson V., Han C.Y., et al. Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler Thromb Vasc Biol. 2011; 31(12):2827–2835. DOI:10.1161/ATVBAHA.111.236554. Epub 2011 Sep 8.; Das A., Durrant D., Salloum F.N., Xi L., Kukreja R.C. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12–21. DOI:10.1016/j.pharmthera.2014.10.003. Epub 2014 Oct 31.; Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11: 214–222. DOI:10.1038/nm1175.; Kim K.H., Kim Y.J., Ohn J.H., Yang J., Lee S.E., Lee S.W., et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012; 125:1390–1401. DOI:10.1161/CIRCULATIONAHA.111.065300. Epub 2012 Feb 8.; Zhang M., Kass D.A. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci. 2011; 32: 360–365. DOI:10.1016/j.tips.2011.02.019.; Igarashi A., Inoue S., Ishii T., Tsutani K., Watanabe H. Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension. Int Heart J. 2016; 57(4):466–472. DOI:10.1536/ihj.15-459. Epub 2016 Jul 7.; Golden S.H., Robinson K.A., Saldanha I., Anton B., Ladenson P.W. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin.Endocrinol. Metab. 2009; 94:1853–1878. DOI:10.1210/jc.2008-2291.; Flegal K.M., Carroll M.D., Ogden C.L., Johnson CL. Рrevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002; 288: 1723–1727.; Geiss L.S., Pan L., Cadwell B. Changes in incidence of diabetes in U.S. adults, 1997–2003. Am. J. Prev. Med. 2006; 30: 371–377. DOI:10.1016/j.amepre.2005.12.009.; Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., Vinicor F., et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000; 23: 1278–1283.; Schmidt M.I., Duncan B.B. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med. 2003; 41(9):1120–1130. DOI:10.1515/CCLM.2003.174.; Singh H., Venkatesan V. Treatment of «Diabesity»: Beyond Pharmacotherapy. Curr Drug Targets. 2018; 19(14):1672–1682. DOI:10.2174/1389450119666180621093833.; Kouidrat Y., Pizzol D., Cosco T., Thompson T., Carnaghi M., Bertoldo A., et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017; 34(9):1185–1192. DOI:10.1111/dme.13403. Epub 2017 Jul 18.; Corona G., Monami M., Rastrelli G., Aversa A., Sforza A., Lenzi A., et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011; 34(6 Pt 1):528–540. DOI:10.1111/j.1365-2605.2010.01117.x. Epub 2010 Oct 24.; Cai X., Tian Y., Wu T., Cao C.X., Li H., Wang K.J. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and metaanalysis of randomized controlled trials. Asian J Androl. 2014; 16(1):146–152. DOI:10.4103/1008-682X.122346.; Aversa A., Vitale C., Volterrani M., Fabbri A., Spera G., Fini M., et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008; 25:37–44. DOI:10.1111/j.1464-5491.2007.02298.x.; Kloner R.A., Comstock G., Levine L.A., Tiger S., Stecher V.J. Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. Expert Opin Pharmacother. 2011; 12:2297–2313. DOI:10.1517/14656566.2011.600306. Epub 2011 Jul 21.; Desouza C., Parulkar A., Lumpkin D., Akers D., Fonseca V.A. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002; 25:1336–1339.; Stirban A., Laude D., Elghozi J.L., Sander D., Agelink M.W., Hilz M.J., et al. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev. 2009; 25:136–143. DOI:10.1002/dmrr.921.; Grover-Paez F., Villegas R.G., Guillen O.R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 78: 136–140. DOI:10.1016/j.diabres.2007.02.006.; Koka S., Aluri H.S., Xi L., Lesnefsky E.J., Kukreja R.C. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1alpha signaling. Am J Physiol Heart Circ Physiol. 2014; 306: H1558– H1568.DOI:10.1152/ajpheart.00865.2013. Epub 2014 Apr 11.; Behr-Roussel D., Oudot A., Compagnie S., Gorny D., Le Coz O., Bernabe J., et al. Impact of a long-term sildenafil treatment on pressor response in conscious rats with insulin resistance and hypertriglyceridemia. Am J Hypertens. 2008; 21(11):1258–1263. DOI:10.1038/ajh.2008.273. Epub 2008 Sep 11.; Ayala J.E., Bracy D.P., Julien B.M., Rottman J.N., Fueger P.T., Wasserman D.H. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes. 2007; 56(4):1025–1033. DOI:10.2337/db06-0883.; Giannetta E., Feola T., Gianfrilli D., Pofi R., Dall’Armi V., Badagliacca R., et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12: 185. DOI:10.1186/s12916-014-0185-3.; Giannetta E., Isidori A.M., Galea N., Carbone I., Mandosi E., Vizza C.D., et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012; 125: 2323–2333. DOI:10.1161/CIRCULATIONAHA.111.063412. Epub 2012 Apr 11.; Lin Y.C., Leu S., Sun C.K., Yen C.H., Kao Y.H., Chang L.T., et al. Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med. 2010; 8: 88. DOI:10.1186/1479-5876-8-88.; Saraiva K.L., Silva A.K., Wanderley M.I., De Araújo A.A., De Souza J.R., Peixoto C.A. Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. Int J Exp Pathol. 2009; 90(4): 454–462. DOI:10.1111/j.1365-2613.2009.00660.x.; Mitschke M.M., Hoffmann L.S., Gnad T., Scholz D., Kruithoff K., Mayer P., et al. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 2013; 27(4):1621–1630. DOI:10.1096/fj.12-221580. Epub 2013 Jan 9.; Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic Syndrome and Urological Diseases. Rev. Urol. 2010; 12(4): 157–180. DOI: 0.3909/riu0487.; Yassin A.A., El-Sakka A.I., Saad F. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Androl. 2008; 40: 259–264. DOI:10.1111/j.1439-0272.2008.00851.x.; Soares M.A., Ezeamuzie O.C., Ham M.J., Duckworth A.M., Rabbani P.S., Saadeh P.B., et al. Targeted protection of donor graft vasculature using a phosphodiesterase inhibitor increases survival and predictability of autologous fat grafts. Plast Reconstr Surg. 2015; 135(2):488– 499. DOI:10.1097/PRS.0000000000000909.; Тюзиков И.А., Калинченко С.Ю., Тишова Ю.А., Ворслов Л.О. Силденафил – новые грани известных фармакотерапевтических опций при лечении эректильной дисфункции. Hi+Med. Высокие технологии в медицине. 2016; 10(47): 58–61.; Ramirez C.E., Nian H., Yu C., Gamboa J.L., Luther J.M., Brown N.J., et al. Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2015;100(12):4533– 4540. DOI:10.1210/jc.2015-3415. Epub 2015 Nov 18.; Koppiker N. Use of cGMP PDE5 inhibitors in the treatment of neuropathy: a review of the patent literature. IDrugs. 2002; 5(5):448–453.; Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J Clin Pract. 2006; 60(9):1123–1126. DOI:10.1111/j.1742-1241.2006.01087.x; Jia L., Wang L., Chopp M., Zhang Y., Szalad A., Zhang Z.G. MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions. Neuroscience. 2016; 329: 43–53. DOI:10.1016/j.neuroscience.2016.05.005. Epub 2016 May 7.; Hatzimouratidis K., Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14(11): 545. DOI:10.1007/s11892-014-0545-6.; La Vignera S., Condorelli R.A., Vicari E., Lotti F., Favilla V., Morgia G., et al. Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase-5 inhibitor. Androl. 2013; 1(2): 245– 250. DOI:10.1111/j.2047-2927.2012.00025.x. Epub 2012 Nov 29.; Wang L., Chopp M., Szalad A., Liu Z., Bolz M., Alvarez F.M., et al. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience. 2011; 193: 399–410. DOI:10.1016/j.neuroscience.2011.07.039. Epub 2011 Jul 27.; Patil C.S., Singh V.P., Singh S., Kulkarni S.K. Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy. Pharmacol. 2004; 72: 190–195. DOI:10.1159/000080104.; Afsar B., Ortiz A., Covic A., Gaipov A., Esen T., Goldsmith D., et al. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol. 2015; 47(9):1521–1528. DOI:10.1007/s11255-015-1071-4. Epub 2015 Aug 5.; Brown K.E., Dhaun N., Goddard J., Webb D.J. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. Hypertension. 2014;63(1):5–11. DOI:10.1161/HYPERTENSIONAHA.113.01774. Epub 2013 Oct 7.; Pofi R., Fiore D., De Gaetano R., Panio G., Gianfrilli D., Pozza C., et al. Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Sci Rep. 2017; 7: 44584. DOI:10.1038/srep44584.; Shen K., Johnson D.W., Gobe G.C. The role of cGMP and its signaling pathways in kidney disease. Am J Physiol Renal Physiol. 2016; 311(4): F671–F681. DOI:10.1152/ajprenal.00042.2016. Epub 2016 Jul 13.; Lasaponara F., Sedigh O., Pasquale G., Bosio A., Rolle L., Ceruti C., et al. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. J Sex Med. 2013;10(11):2798–2814. DOI:10.1111/jsm.12038. Epub 2013 Jan 24.; Vecchio M., Navaneethan S.D., Johnson D.W., Lucisano G., Graziano G., Querques M., et al. Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials. Clin J Am Soc Nephrol. 2010;5(6):985–995. DOI:10.2215/CJN.09081209. Epub 2010 May 24.; Pace G., Palumbo P., Miconi G., Silvestri V., Cifone M.G., Vicentini C. PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study. World J Urol. 2011;29(2):243–248. DOI:10.1007/s00345-010-0517-7. Epub 2010 Feb 23.; Taskin M.I., Yay A., Adali E., Balcioglu E., Inceboz U. Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats. Gynecol Endocrinol. 2015;31(4):272–277. DOI:10.3109/09513590.2014.984679. Epub 2014 Dec 8.; El-Sayed M.A., Saleh S.A., Maher M.A., Khidre A.M. Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate. J Matern Fetal Neonatal Med. 2018; 31(8): 1045–1050. DOI:10.1080/14767058.2017.1306509. Epub 2017 Mar 27.; Oyston C., Stanley J.L., Oliver M.H., Bloomfield F.H., Baker P.N. Maternal Administration of Sildenafil Citrate Alters Fetal and Placental Growth and Fetal-Placental Vascular Resistance in the Growth-Restricted Ovine Fetus. Hypertension. 2016; 68(3):760–767. DOI:10.1161/HYPERTENSIONAHA.116.07662. Epub 2016 Jul 18.; Russo F.M., Toelen J., Eastwood M.P., Jimenez J., Miyague A.H., Vande Velde G., et al. Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia. Thorax. 2016; 71(6): 517–525. DOI:10.1136/thoraxjnl-2015-207949. Epub 2016 Mar 17.; Tiboni G.M., Ponzano A. Prevention of valproic acid-induced neural tube defects by sildenafil citrate. Reprod Toxicol. 2015; 56: 175–179. DOI:10.1016/j.reprotox.2015.03.004. Epub 2015 Mar 20.; Dunn L., Flenady V., Kumar S. Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial. J Transl Med. 2016; 14: 15. DOI:10.1186/s12967-016-0769-0.; George E.M., Palei A.C., Dent E.A., Granger J.P. Sildenafil attenuates placental ischemiainduced hypertension. Am J Physiol Regul Integr Comp Physiol. 2013; 305(4):R397–403. DOI:10.1152/ajpregu.00216.2013. Epub 2013 Jun 19.; Villanueva-García D., Mota-Rojas D., Hernández-González R., Sánchez-Aparicio P., Alonso-Spilsbury M., Trujillo-Ortega M.E., et al. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol. 2007; 27(3):255–259. DOI:10.1080/01443610701194978.; Maher M.A., Sayyed T.M., Elkhouly N. Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. Obstet Gynecol. 2017; 129(4): 615–620. DOI:10.1097/AOG.0000000000001928.; Trapani A.Jr., Gonçalves L.F., Trapani T.F., Vieira S., Pires M., Pires M.M. Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial. Obstet Gynecol. 2016; 128(2): 253–259. DOI:10.1097/AOG.0000000000001518.; Paauw N.D., Terstappen F., Ganzevoort W., Joles J.A., Gremmels H., Lely A.T. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. Hypertension. 2017; 70(5):998–1006. DOI:10.1161/HYPERTENSIONAHA.117.09690. Epub 2017 Sep 11.; Dunn L., Greer R., Flenady V., Kumar S. Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes. Fetal Diagn Ther. 2017; 41(2):81–88. DOI:10.1159/000453062. Epub 2016 Dec 8.; Biyiksiz P.C., Filiz S., Vural B. Is sildenafil citrate affect endometrial receptivity? An immunohistochemical study. Gynecol Endocrinol. 2011; 27(10):767–774. DOI:10.3109/09513590.2010.540601. Epub 2010 Dec 29.; Takasaki A., Tamura H., Miwa I., Taketani T., Shimamura K., Sugino N. Endometrial growth and uterine blood flow: a pilot study for improving endometrialthickness in the patients with a thin endometrium. Fertil Steril. 2010; 93(6):1851–1858. DOI:10.1016/j.fertnstert.2008.12.062. Epub 2009 Feb 6.; Zinger M., Liu J.H., Thomas M. A. Successful use of vaginal sildenafil citrate in two infertility patients with Asherman’s syndrome. J Womens Health (Larchmt). 2006; 15(4):442– 444. DOI:10.1089/jwh.2006.15.442.; Nurnberg H.G., Hensley P.L., Heiman J.R., Croft H.A., Debattista C., Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008; 300(4):395–404.DOI:10.1001/jama.300.4.395.; Gao L., Yang L., Qian S., Li T., Han P., Yuan J. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. Int J Gynaecol Obstet. 2016; 133(2):139–145. DOI:10.1016/j.ijgo.2015.08.015. Epub 2015 Dec 17.; Гамидов С.И., Овчинников Р.И., Попова А.Ю. Мужское бесплодие и эректильная дисфункция: влияние ингибиторов фосфодиэстеразы 5-го типа на сперматогенез. РМЖ. 2015; 11:626.; Aversa A., Mazzilli F., Rossi T., Delfino M., Isidori A.M., Fabbri A. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod. 2000; 15(1): 131–134.; Purvis K., Muirhead G.J., Harness J.A. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol. 2002; 53(Suppl. 1): 53–60. DOI:10.1046/j.0306-5251.2001.00033.x; Du Plessis S.S., de Jongh P.S., Franken D.R. Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril. 2004; 81(4):1026–1033. DOI:10.1016/j.fertnstert.2003.09.054.; Jannini E.A., Lombardo F., Salacone P. Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate. Fertil Steril. 2004; 81(3): 705–707.; Drobnis E.Z., Nangia A.K. Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction. Adv Exp Med Biol. 2017; 1034: 29–38. DOI:10.1007/978-3-319-69535-8_5.; Tan P., Liu L., Wei S., Tang Z., Yang L., Wei Q. The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Metaanalysis and Systematic Review. Urol. 2017; 105:54–61. DOI:10.1016/j.urology.2017.02.032. Epub 2017 Mar 1.; Dimitriadis F., Giannakis D., Pardalidis N., Zikopoulos K., Paraskevaidis E., Giotitsas N., et al. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. Asian J Androl. 2008;10(1):115–133. DOI:10.1111/j.1745-7262.2008.00373.x; Mostafa T. Oral phosphodiesterase-5 inhibitors and sperm functions. Int J Impot Res. 2008;20(6): 530– 536. DOI:10.1038/ijir.2008.29. Epub 2008 Jul 3.; Epstein P.M., Hachisu R. Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984; 16: 303–324.; Joe A.K., Liu H., Xiao D., Soh J.W., Pinto J.T., Beer D.G., et al. Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol. 2003; 3: 83–94.; Lim J.T., Piazza G.A., Pamukcu R., Thompson W.J., Weinstein I.B. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin Cancer Res. 2003;9:4972–4982.; Piazza G.A., Thompson W.J., Pamukcu R., Alila H.W., Whitehead C.M., Liu L., et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001; 61: 3961–3968.; Singer A.L., Sherwin R.P., Dunn A.S., Appleman M.M. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues. Cancer Res. 1976; 36: 60–66.; Whitehead C.M., Earle K.A., Fetter J., Xu S., Hartman T., Chan D.C., et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003;2:479–488.; Zhu B., Vemavarapu L., Thompson W.J., Strada S.J. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005; 94: 336–350. DOI:10.1002/jcb.20286.; Karami-Tehrani F., Moeinifard M., Aghaei M., Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012; 43:470–475. DOI:10.1016/j.arcmed.2012.08.006. Epub 2012 Sep 7.; Sarfati M., Mateo V., Baudet S., Rubio M., Fernandez C., Davi F., et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood. 2003; 101: 265–269. DOI:10.1182/blood-2002-01-0075.; Li N., Xi Y., Tinsley H.N., Gurpinar E., Gary B.D., Zhu B., et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/betacatenin signaling. Mol Cancer Ther. 2013; 12:1848–1859. DOI:10.1158/1535-7163.MCT-13-0048. Epub 2013 Jun 26.; Tinsley H.N., Gary B.D., Keeton A.B., Lu W., Li Y., Piazza G.A. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila). 2011; 4: 1275–1284. DOI:10.1158/1940-6207.CAPR-11-0095. Epub 2011 Apr 19.; Booth L., Roberts J.L., Cruickshanks N., Tavallai S., Webb T., Samuel P., et al. PDE5 inhibitors enhance Celecoxib killing in multiple tumor types. J Cell Physiol. 2015; 230(5): 1115–1127. DOI:10.1002/jcp.24843.; Das A., Durrant D., Mitchell C., Mayton E., Hoke N.N., Salloum F.N., et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA. 2010; 107: 18202–18207. DOI:10.1073/pnas.1006965107. Epub 2010 Sep 30.; Booth L., Roberts J.L., Cruickshanks N., Conley A., Durrant D.E., Das A., et al. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol. 2014; 85: 408–419. DOI:10.1124/mol.113.090043. Epub 2013 Dec 18.; Roberts J.L., Booth L., Conley A., Cruickshanks N., Malkin M., Kukreja R.C., et al. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther. 2014; 15: 758–767. DOI:10.4161/cbt.28553. Epub 2014 Mar 20.; El-Naa M.M., Othman M., Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther. 2016; 10: 3661-3672. DOI:10.2147/DDDT.S107490.; https://www.med-sovet.pro/jour/article/view/2837

الاتاحة: https://www.med-sovet.pro/jour/article/view/2837
https://doi.org/10.21518/2079-701X-2018-21-192-202

المؤلفون: N. D. Akhvlediani, S. N. Allenov, I. P. Matyukhov, Z. S. Inoyatov

المصدر: Медицинский совет, Vol 0, Iss 2, Pp 28-32 (2015)

مصطلحات موضوعية: эректильная дисфункция, консервативная терапия, ингибиторы фдэ 5-го типа, силденафил, олмакс стронг, erectile dysfunction, conservative therapy, inhibitors of pde type 5, sildenafil, olmax strong, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/115; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/32ace585234a4f2bb8f39e6bba0835d7

المؤلفون: S. I. Gamidov, R. I. Ovchinnikov, A. Y. Popova

المصدر: Медицинский совет, Vol 0, Iss 11, Pp 54-59 (2015)

مصطلحات موضوعية: эректильная дисфункция, фармакотерапия, ингибиторы, фосфодиэстеразы-5, силденафил, bacteriophage, infections, phage therapy, antibiotic resistance, infectious and inflammatory diseases, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/290; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/d82a80e13d364a65b4d043a93c016e87

المؤلفون: E. I. Karpov

المصدر: Медицинский совет, Vol 0, Iss 17, Pp 104-107 (2015)

مصطلحات موضوعية: эректильная дисфункция, ингибиторы, фосфодиэстеразы 5-го типа, факторы риска, лечение неэффективность ифдэ-5, силденафил эрексезил®, erectile dysfunction, phosphodiesterase type 5 inhibitors, risk factors, treatment, failure of ipde-5, sildenafil, erexes, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/434; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/02a76dd46d9e483c8f879467275dce3e

المؤلفون: Z. S. Valieva, Z. H. Dadacheva, T. V. Martynyuk, N. M. Danilov, M. A. Saidova, I. Ye. Chazova

المصدر: Евразийский Кардиологический Журнал, Vol 0, Iss 4, Pp 40-47 (2015)

مصطلحات موضوعية: idiopathic pulmonary hypertension, phosphodiesterase type 5 inhibitor, sildenafil, идиопатическая лёгочная гипертензия, лаг-специфическая терапия, ингибитор фосфодиэстеразы типа 5, силденафил, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.heartj.asia/jour/article/view/5654; https://doaj.org/toc/2225-1685; https://doaj.org/toc/2305-0748

URL الوصول: https://doaj.org/article/35ed9841b90445bba73f9d49812e4613

المؤلفون: N. A. Shostak, A. A. Klimenko, N. A. Demidova

المصدر: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 1, Pp 73-78 (2015)

مصطلحات موضوعية: редкие заболевания, орфанные препараты, хроническая тромбоэмболическая легочная гипертензия, илопрост, бозентан, силденафил, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/145; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

URL الوصول: https://doaj.org/article/89184224d81845b09094f6ac3fe8436a

المؤلفون: Т. В. Мартынюк, З. Х. Дадачева, И. Е. Чазова

المصدر: Атеротромбоз, Vol 0, Iss 1, Pp 87-98 (2015)

مصطلحات موضوعية: легочная гипертензия, хроническая тромбоэмболическая легочная гипертензия, тромбэндартерэктомия, бозентан, простаноиды, силденафил, риоцигуат, Internal medicine, RC31-1245

وصف الملف: electronic resource

Relation: https://www.aterotromboz.ru/jour/article/view/10; https://doaj.org/toc/2307-1109; https://doaj.org/toc/2658-5952

URL الوصول: https://doaj.org/article/d67a9903c05c411888a3e6666cda8351

المؤلفون: T. V. Martynyuk, Z. H. Dadacheva, V. M. Paramonov, O. A. Arkhipova, S. N. Nakonechnikov, I. Ye. Chazova

المصدر: Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 42-49 (2015)

مصطلحات موضوعية: легочная гипертензия, легочная артериальная гипертензия, хроническая тромбоэмболическая лёгочная гипертензия, оксид азота, цгмф, ингибиторы фосфодиэстеразы типа 5, силденафил, pulmonary hypertension, pulmonary arterial hypertension, nitric oxide, cyclic guanosine-monophosphate, pde-5 inhibitors, sildenafil, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.heartj.asia/jour/article/view/5633; https://doaj.org/toc/2225-1685; https://doaj.org/toc/2305-0748

URL الوصول: https://doaj.org/article/dfa238de8fca45f99e0724176c2c8420

المؤلفون: A. Volkov V., N. Yudkina N., E. Nikolaeva V., I. Kurmukov A., А. Волков В., Н. Юдкина Н., Е. Николаева В., И. Курмуков А.

المصدر: Rheumatology Science and Practice; Vol 56, No 1 (2018); 117-122 ; Научно-практическая ревматология; Vol 56, No 1 (2018); 117-122 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20181

مصطلحات موضوعية: systemic sclerosis, pulmonary arterial hypertension, iloprost, bosentan, ambrisentan, sildenafil, survival, lung diffusion capacity, системная склеродермия, легочная артериальная гипертензия, илопрост, бозентан, амбризентан, силденафил, выживаемость, диффузионная способность легких

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2509/1667; Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. New Engl J Med. 2004 Sep 30;351(14):142536. doi:10.1056/NEJMra040291; Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-63. doi:10.1161/CIRCULATIONAHA.109.911818; Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:S40-S47. doi:10.1016/j.jacc.2004.02.032; Galie N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537. doi:10.1093/eurheartj/ehp297; Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 Aug 21;40(4):780-8. doi:10.1016/S0735-1097(02)02012-0; Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21;132(6):425-34. doi:10.7326/0003-4819132-6-200003210-00027; Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J. 2009 Jul;34(1):132-7. doi:10.1183/09031936.00130408; Knudsen L, Schurawlew A, Nickel N, et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC Pulm Med. 2011 Dec 1;11:56. doi:10.1186/1471-2466-11-56; Galie N, Barbera JA, Frost AE, et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-44. doi:10.1056/NEJMoa1413687; Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014 Jun;43(6):1691-7. doi:10.1183/09031936.00116313; Волков АВ, Мартынюк ТВ, Юдкина НН и др. Выживаемость пациентов с легочной артериальной гипертензией, ассоциированной с системной склеродермией. Терапевтический архив. 2012;84(5):24-8 [Volkov AV, Martynyuk TV, Yudkina NN, et al. Survival of patients with pulmonary arterial hypertension, associated with systemic sclerosis. Terapevticheskii Arkhiv. 2012;84(5):24-8 (In Russ.)].; Rubenfire M, Huffman MD, Krishnan S, et al. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest. 2013 Oct;144(4):1282-90. doi:10.1378/chest.12-0653; Юдкина НН, Валеева ЭГ, Таран ИН и др. Легочная артериальная гипертензия, ассоциированная с системной склеродермией, и идиопатическая легочная гипертензия: сравнительный анализ клинико-демографических особенностей и выживаемости по данным Российского национального регистра. Системные гипертензии. 2016;13(2):65-72 [Yudkina NN, Valeeva EG, Taran IN, et al. Demographic and clinical differences between idiopathic and scleroderma-related pulmonary arterial hypertension: Russian National Registry analysis. Sistemnye Gipertenzii = Systemic Hypertension. 2016;13(2):65-72 (In Russ.)].; Николаева ЕВ, Юдкина НН, Курмуков ИА и др. Клиникогемодинамическая характеристика и возможности терапии у больных тяжелой легочной артериальной гипертензией IV функционального класса, ассоциированной с системными заболеваниями соединительной ткани. Терапевтический архив. 2015;87(5):24-32 [Nikolaeva EV, Yudkina NN, Kurmukov IA, et al. Clinical and hemodynamic characteristics and possibilities for therapy in patients with severe (functional class IV) pulmonary arterial hypertension associated with diffuse connective tissue diseases. Terapevticheskii Arkhiv. 2015;87(5):24-32 (In Russ.)]. doi:10.17116/terarkh201587524-32; Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-9. doi:10.1183/09031936.04.00028404; Coghlan JG, Galie N, Barbera JA, et al; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul;76(7):1219-27. doi:10.1136/annrheumdis-2016-210236; Volkov A, Nikolaeva E, Yudkina N, Kurmukov I. Reversibility of pulmonary arterial hypertension, associated with systemic sclerosis: can it really be true? J Scleroderm Relat Disord. 2016;1(1):66. doi:10.5301/jsrd.5000203; https://rsp.mediar-press.net/rsp/article/view/2509

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2509
https://doi.org/10.14412/1995-4484-2018-117-122

المؤلفون: D. I. Sadykova, D. R. Sabirova, N. V. Kustova, N. N. Firsova, G. A. Khusnullina

المصدر: Rossijskij Vestnik Perinatologii i Pediatrii, Vol 63, Iss 5, Pp 167-171 (2018)

مصطلحات موضوعية: дети, легочная артериальная гипертензия, врожденный порок сердца, диагностика, лечение, силденафил, Pediatrics, RJ1-570

Relation: https://www.ped-perinatology.ru/jour/article/view/744; https://doaj.org/toc/1027-4065; https://doaj.org/toc/2500-2228; https://doaj.org/article/d491a2a178ac465499e292e8d2847e00

الاتاحة: https://doi.org/10.21508/1027-4065-2018-63-5-167-171
https://doaj.org/article/d491a2a178ac465499e292e8d2847e00

المؤلفون: PI Rasner, DY Pushkar

المصدر: Медицинский совет, Vol 0, Iss 19, Pp 64-71 (2014)

مصطلحات موضوعية: эректильная дисфункция, терапия, ингибиторы фосфодиэстеразы 5-го типа, силденафил, erectile dysfunction, therapy, phosphodiesterase type 5 inhibitors, sildenafil, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/809; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/3ae08b049cbb479491a1df4b3275a110

المؤلفون: Z. H. Dadacheva, T. V. Martynyuk, M. A. Saidova, N. M. Danilov, K. V. Mershin, I. Ye. Chazova

المصدر: Евразийский Кардиологический Журнал, Vol 0, Iss 4, Pp 34-42 (2014)

مصطلحات موضوعية: легочная гипертензия, хроническая тромбоэмболическая лёгочная гипертензия, ингибитор фосфодиэстеразы типа 5, силденафил, pulmonary hypertension, chronic thromboembolic pulmonary hypertension, phosphodiesterase type 5 inhibitor, sildenafil, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.heartj.asia/jour/article/view/5614; https://doaj.org/toc/2225-1685; https://doaj.org/toc/2305-0748

URL الوصول: https://doaj.org/article/1467e5ecd18845fe8742f80ce37168f9

المؤلفون: V. V. Bystrov, O. A. Arkhipova, T. V. Martynyuk, M. A. Saidova, O. V. Stukalova, N. M. Danilov, T. A. Sakhnova, I. Ye. Chazova

المصدر: Евразийский Кардиологический Журнал, Vol 0, Iss 4, Pp 26-33 (2014)

مصطلحات موضوعية: идиопатическая лёгочная гипертензия, комбинированная лаг-специфическая терапия, антагонист рецепторов эндотелина, эндотелин-1, ингибитор фосфодиэстеразы типа 5, бозентан, силденафил, phosphodiesterase type 5 inhibitor, sildenafil, idiopathic pulmonary hypertension, endothelin receptor antagonists, bosentan, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.heartj.asia/jour/article/view/5611; https://doaj.org/toc/2225-1685; https://doaj.org/toc/2305-0748

URL الوصول: https://doaj.org/article/3fe4af5cb3884e8f9ef6f68e14ca42c6

المؤلفون: T. Martynyuk V., S. Nakonechnikov N., I. Chazova Ye., Т. Мартынюк В., С. Наконечников Н., И. Чазова Е.

المصدر: Meditsinskiy sovet = Medical Council; № 5 (2017); 10-18 ; Медицинский Совет; № 5 (2017); 10-18 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-5

مصطلحات موضوعية: pulmonary arterial hypertension, combined specific therapy, COMPASS-2, RESPITE, sildenafil, riociguatum, легочная артериальная гипертензия, комбинированная специфическая терапия, СOMPASS-2, силденафил, риоцигуат

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1783/1724; Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Современные подходы к лечению пациентов с легочной гипертензией в свете рекомендаций Европейского общества кардиологов. Consilium Medicum, 2005, 11: 957-962.; Чазова И.Е., Авдеев С.Н., Царева Н.А., др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический архив, 2014, 9: 4-23.; Galiè N, Hoeper MM, Humbert M, et al. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)), endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), the International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal (2016, 37(1): 67-119.; Taichman DB, Ornelas J, Chung L et al. Pharmacologic therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report. CHEST, 2014, 146(2): 449-475.; Мартынюк Т.В., Архипова О.А., Кобаль Е.А., др. Применение неселективного антагониста рецепторов эндотелина бозентана у больных идиопатической легочной гипертензией: первый российский опыт и взгляд в будущее. Cистемные гипертензии, 2011, 4: 51-57.; Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. 2013г. Доступно по ссылке: http://www. cardioweb.ru/klinicheskie-rekomendatsii; Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update For The Diagnosis And Management Of Chronic Heart Failure In The Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112: e154-e235.; Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the neardead to multiple clinical trial meta-analyses. Eur Heart J, 2010, 31: 2080-2086.; Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J, 2004, 24: 1007-1010.; Dardi F, Manes A, Palazzini M, et al.Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: realworld insights. Eur Respir J, 2015, 46: 414-421.; Парамонов В.М. Оценка эффективности длительной терапии бозентаном, силденфилом и их комбинации у больных идиопатической легочной гипертензией. Автореф. дисс. канд. мед. наук. М., 2016. (Доступно по ссылке: http://rsmu.ru/fileadmin/rsmu/img/about_rsmu/disser/8/d_paramonov_vm.pdf).; Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J, 2007, 29: 469-475.; Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol, 2002, 40: 780-788.; Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology, 2011, 120(3): 157-165.; McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J, 2015, 46(2): 405-13.; Liu H, Chen X, Li J, et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension A Meta-analysis of Randomized Controlled Trial. CHEST, 2016, 150(2): 353-366.; Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2013, 188: 639-646.; Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol, 2005, 99(1): 91-5.; Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest, 2004, 125: 580-586.; Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 2011, 123(20): 2263-2273.; Hoeper MM, Klinger JR, Benza RL, et al. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122: 18-22.; Nazzareno Galie et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension – web addenda. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and of the European Respiratory Society (ERS). European Heart Journal. Available at: (doi:10.1093/eurheartj/ehv317); https://www.med-sovet.pro/jour/article/view/1783

الاتاحة: https://www.med-sovet.pro/jour/article/view/1783
https://doi.org/10.21518/2079-701X-2017-5-10-18

المؤلفون: Горпинченко, І. І., Ситенко, А. М.

المصدر: Health of Man; No. 3(62) (2017); 66-70 ; Здоровье мужчины; № 3(62) (2017); 66-70 ; Здоров'я чоловіка; № 3(62) (2017); 66-70 ; 2412-5547 ; 2307-5090

مصطلحات موضوعية: erectile dysfunction, treatment, sildenafil, spray, Strondex, 616.69-008.1-02-092, эректильная дисфункция, лечение, силденафил, спрей, Строндекс, еректильна дисфункція, лікування, силденафіл

وصف الملف: application/pdf

Relation: http://health-man.com.ua/article/view/117839/111860; http://health-man.com.ua/article/view/117839

الاتاحة: http://health-man.com.ua/article/view/117839
https://doi.org/10.30841/2307-5090.3(62).2017.117839